Try Alerts Free   |   Login
Health Care › Biological Products (No Diagnostic Substances)

Seneca Biopharma (SNCA) Financials and Smart Investor 13F Alerts

See how revenue, income, cash flow, and balance sheet financials have changed over 36 quarters since 2012. Compare with SNCA stock chart to see long term trends.

SNCA stock compared to

SNCA Income Statement

Revenue, Net:2500
Revenue Per Share:0
Research & Development Expense:409519
Total Operating Expenses:4396592
Operating Income:-4394092
Net Income:-4418839
Earnings Per Share, Basic:0.04
Shares Outstanding, Basic Avg:13869272

SNCA Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:9756
Change in Accounts Receiveable:107500
Net Cash from Operations:-2194581
Net Cash from Financing Activities:0
Net Change in Cash & Equivalents:-2197576

SNCA Balance Sheet

Cash and Cash Equivalents:10554519
Accounts Receivable, Net:116279
Total Current Assets:12880796
Property, Plant & Equipment, Net:10776
Total Assets:13049144
Total Short-Term Liabilities:3205930
Total Liabilities:3281228

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Sabby Management, LLC
393,411 sh
278,410 sh
242%
$229
$146
Renaissance Technologies LLC
260,818 sh
-183,805 sh
-41%
$152
-$168
Virtu Financial LLC
28,544 sh
-3,025 sh
-10%
$17
-$6
Blackrock Inc.
3,509 sh
 
$2
Morgan Stanley
56 sh
 
$0
Bank Of America Corp /De/
27 sh
6 sh
29%
$0
Royal Bank Of Canada
4 sh
4 sh
NEW
$0
Northern Trust Corp
0 sh
-11,961 sh
-100%
$0
-$9
Proequities, Inc.
0 sh
 
$0

Data imported from Seneca Biopharma, Inc. SEC filings. Check original filings before making any investment decision.